Dicerna Pharmaceuticals, Inc. (DRNA) News
Filter DRNA News Items
DRNA News Results
|Loading, please wait...|
DRNA News Highlights
- 500 - Internal server error
- Over the past 20 days, the trend for DRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest DRNA News From Around the Web
Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
LEXINGTON, Mass., Jun 16, 2021--Dicerna announced it has completed dosing in the Company’s PHYOX™4 clinical trial, evaluating nedosiran for the treatment of patients with PH3.
Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.
Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference.
We have been pretty impressed with the performance at Dicerna Pharmaceuticals, Inc. ( NASDAQ:DRNA ) recently and CEO...
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Dicerna announced the U.S. FDA's acceptance of the Investigational New Drug (IND) application filed by Lilly for LY3819469.
Are we at the start of a boom or a bust? That’s the question on investors’ minds these days, as the world gets back on its feet following the COVID crisis. The recent April jobs report, with its mix of good and bad news, puts the question into sharp relief. First, the good news. April saw 266,000 new jobs created. On the negative side, economists had predicted as many as 1 million. The expectation has been that this economic recovery will be heavily front-loaded regarding job recreation – the theory is, the jobs are there; they are just waiting for workers to go back to them. That’s not quite happening.
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -39.29% and -20.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Dicerna today reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY). Dicerna became entitled to royalties on worldwide net product sales of Oxlumo as part of a 2020 non-exclusive intellectual property cross-license agreement between Dicerna and Alnylam related to the companies' PH programs. Dicerna is entitled to royalties in the mid to high single digits based on OXLUMO global net sales. This transaction, together with Dicerna's cash, ...